More Racura Oncology Ltd news
Racura Oncology LtdASX: RAC

S&P DJI Announces March 2024 Quarterly Rebalance

Mar 1, 2024 at 6:24 AM EST · Issued by Racura Oncology Ltd

Filed with ASX · Mar 1, 2024 at 6:24 AM EST · 8 pages · English

On 6ix: 6ix.com/news/sandp-dji-announces-march-2024-quarterly-rebalance-23

Racura Oncology Ltd on 6ix

Earlier from Racura Oncology

  • Race Receives $4.0m R&D Tax Refund for Financial Year 2023Feb 27, 2024
  • December 2023 Preclinical & Clinical Program UpdateDec 29, 2023
  • Bonus Options ProspectusNov 21, 2023
  • Updated Strategy and Investor PresentationNov 21, 2023
  • Dr Daniel Tillett appointed CEO of Race OncologyNov 21, 2023

Later from Racura Oncology

  • Bisantrene shows potent anticancer activity in AML modelsMar 5, 2024
  • RC220 cGMP Manufacturing CompleteMar 25, 2024
  • Quarterly Activity Report & Appendix 4CApr 18, 2024
  • Bisantrene with Decitabine Enhances Cancer Cell KillingMay 13, 2024
  • US FDA Orphan Drug Designation Awarded to RC220 BisantreneJun 10, 2024
All Racura Oncology news releases↗

Follow Racura Oncology into a list and get an email when it puts out news.

Follow Racura Oncology
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer